Buying a Bitcoin ETF means owning shares in a fund that holds Bitcoin, not owning Bitcoin directly. If the ETF provider, like BlackRock's IBIT, goes bankrupt, the Bitcoin remains protected in a separate trust with custodians like Coinbase Custody. However, risk exists if the custodian fails, as they safeguard the actual Bitcoin. Investors should understand ETF shares carry Bitcoin price risk but are legally distinct from the provider's assets, offering some protection compared to holding Bitcoin on unregulated platforms.
The story about Bitcoin ETF safety provides context for cryptocurrency market activity. For readers following cryptocurrencies, here is Pluang's market snapshot as of Sep 18, 2026 21:36 WIB: out of 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell. Notable movers include SXP (Solar) down 46.27% at Rp37 with a typical hold time of 94 days, UNI (Uniswap) up 21.80% at Rp157,002 with a typical hold time of 65 days and Pluang order activity of 37% Sell / 63% Buy, and THETA (Theta Network) up 12.84% at Rp3,664 with a typical hold time of 77 days and 0% Sell / 100% Buy order activity.
McCormick & Company reported strong Q2 results with a 30.1% rise in adjusted operating income and a 16.7% increase in sales. The company, known for its long history of dividend increases, trades at about 16 times projected 2026 earnings and offers a ...
Grayscale Bitcoin Mini Trust (BTC) rose about 5.8% following Bitcoin's rebound above $80,000, reflecting renewed investor interest after the U.S. Senate failed to advance the CLARITY Act. The trust offers exposure to Bitcoin without direct ownership ...
Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...
Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...
Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...
